Below are the most recent publications written about "Glucagon-Like Peptide-1 Receptor" by people in Profiles.
-
Vear A, Heneka MT, Clemmensen C. Incretin-based therapeutics for the treatment of neurodegenerative diseases. Nat Metab. 2025 Apr; 7(4):679-696.
-
Valdecantos MP, Ruiz L, Folgueira C, Rada P, Gomez-Santos B, Solas M, Hitos AB, Field J, Francisco V, Escalona-Garrido C, Zagmutt S, Calderon-Dominguez M, Mera P, Garcia-Martinez I, Maym?-Masip E, Grajales D, Alen R, Mora A, S?inz N, Vides-Urrestarazu I, Vilarrasa N, Arbones-Mainar JM, Zaragoza C, Moreno-Aliaga MJ, Aspichueta P, Fern?ndez-Veledo S, Vendrell J, Serra D, Herrero L, Schreiber R, Zechner R, Sabio G, Hornigold D, Rondinone CM, Jermutus L, Grimsby J, Valverde ?M. The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk. Nat Commun. 2024 11 28; 15(1):10342.
-
Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, Banker A, Husami Z, Labib S, Venesy D, Fonarow G, Kosiborod M, Al-Kindi S, Bhatt DL, Dani S, Nohria A, Butler J, Ganatra S. GLP-1 Receptor Agonists Among Patients?With Overweight or Obesity,?Diabetes,?and HFpEF on SGLT2?Inhibitors. JACC Heart Fail. 2024 Nov; 12(11):1814-1826.
-
Bales MB, Centanni SW, Luchsinger JR, Fathi P, Biddinger JE, Le TDV, Nwaba KG, Paldrmic IM, Winder DG, Ayala JE. High fat diet blunts stress-induced hypophagia and activation of Glp1r dorsal lateral septum neurons in male but not in female mice. Mol Metab. 2022 10; 64:101571.
-
Cheng Z, Guo D, Ruzi A, Pan T, You K, Chen Y, Huang X, Zhang J, Yang F, Niu L, Xu K, Li YX. Modeling MEN1 with Patient-Origin iPSCs Reveals GLP-1R Mediated Hypersecretion of Insulin. Cells. 2022 08 03; 11(15).
-
Al Rifai M, Vaughan EM, Abushamat LA, Lee M, Ramsey DJ, Gupta K, Navaneethan SD, Virani SS. Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs). Am J Cardiol. 2022 06 01; 172:7-10.
-
Chipkin SR. Tirzepatide for Patients With Type 2 Diabetes. JAMA. 2022 02 08; 327(6):529-530.
-
Mahtta D, Ramsey DJ, Lee MT, Chen L, Al Rifai M, Akeroyd JM, Vaughan EM, Matheny ME, Santo KRDE, Navaneethan SD, Lavie CJ, Birnbaum Y, Ballantyne CM, Petersen LA, Virani SS. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
-
Roth J, Ashcroft FM, Wollheim CB, Kieffer TJ, Cherrington AD, Bergman RN, Taylor R, Najjar SM, Pedersen O, Ellingsgaard H, Holst JJ, Nauck MA, Kadowaki T, Czech MP, Corvera S, Saltiel AR, Corkey BE, Atkinson MA. Voices: Insulin and beyond. Cell Metab. 2021 04 06; 33(4):692-699.
-
Chang HY, Chou YY, Tang W, Chang GM, Hsieh CF, Singh S, Tung YC. Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan. Sci Rep. 2021 03 26; 11(1):7000.